Novavax Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones

2025.12.02 22:33

I'm PortAI, I can summarize articles.

Novavax Inc.'s stock fell 1.35% to $6.60 on Tuesday, underperforming compared to competitors like Johnson & Johnson, which rose slightly. The NASDAQ and Dow Jones indices both saw gains. Novavax's stock is 42.86% below its 52-week high. Trading volume was 2.5 million, below the 50-day average of 4.2 million.

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Novavax Inc. (NVAX) slid 1.35% to $6.60 Tuesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite Index rising 0.59% to 23,413.67 and the Dow Jones Industrial Average rising 0.39% to 47,474.46. This was the stock's second consecutive day of losses. Novavax Inc. closed 42.86% short of its 52-week high of $11.55, which the company reached on January 7th. The stock underperformed when compared to some of its competitors Tuesday, as Johnson & Johnson (JNJ) rose 0.04% to $205.42, Pfizer Inc. (PFE) fell 0.47% to $25.15, and Merck & Co. Inc. (MRK) fell 0.79% to $101.03. Trading volume (2.5 M) remained 1.7 million below its 50-day average volume of 4.2 M. Data source: Dow Jones Market Data, FactSet. Data compiled December 2, 2025. This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires 12-02-25 1733ET